Detecting Colorectal Cancer Early Saves Lives. Get the Blood Test that Finds it Early.

ColonSentry® is an easy blood test that uses advanced gene expression (mRNA) technology to help identify Colorectal Cancer (CRC) early when it’s most treatable(1).

About The ColonSentry Test

ColonSentry, is the first liquid biopsy for CRC, using our patented Sentinel Principle Technology Platform and has been used on more than 100,000 patients nationwide. If your ColonSentry score is elevated, there is an increased probability you may have Colorectal Cancer. (1-3)

  • No Dietary Restrictions​
  • No Need to Handle Messy Stool
  • No Preparation Required
  • No Time Off Work​

Why Get Tested?

When Colorectal Cancer is found early, the five-year survival rate is 91%. When Colorectal Cancer is found late, the five-year survival rate is 14%.(4) ColonSentry needs to be prescribed by a physician and is available through AVRT,  our comprehensive telehealth program that uses advanced diagnostics and physician supervision to help patients detect cancer in the earliest stages. Whether you have a family history of cancer or are simply concerned about developing cancer, our physicians can work with you to develop a patient-centric, personalized care plan to help optimize your health.

How it Works

Complete your online intake form to determine your eligibility for testing.

After you make your secure online payment for your test, we’ll schedule testing at a lab near your or arrange for a mobile phlebotomist to come to your home.

When we receive your test results, we’ll reach out to schedule a time to review them with a telehealth physician.

Contact Us to get Started!

Fill out the form below and an AVRT representative will reach out to you soon to answer any questions you may have.

Name(Required)
Location
By submitting this form, you are confirming that you would like to receive information on the AVRT telehealth program. You can unsubscribe at any time.
This field is for validation purposes and should be left unchanged.

Additional Testing for Early Cancer Detection

In addition to the AVRT panel, we offer advanced blood tests for early cancer detection*. These tests are offered by StageZero Life Sciences, a CLIA Certified, CAP Accredited High Complexity Laboratory in Richmond, VA.  Be sure to ask your case manager about any of the tests below. Pricing and availability vary.

ARISTOTLE®

Aristotle is a blood test that uses advanced mRNA technology to identify the molecular signatures of multiple cancers from a single sample of blood. (5)

Learn More

ColonSentry®

ColonSentry is a blood test that uses advanced mRNA gene expression technology to help identify Colorectal Cancer (CRC) early when it’s most treatable. (1-3)

Learn More

BreastSentry™

BreastSentry is a blood test that can help identify if a woman has an increased risk for developing breast cancer. (6)

Learn More

PHI

The Prostate Health Index is a FDA approved blood test that can help men with elevated PSA differentiate benign prostate conditions from prostate cancer. (7,8)

Learn More

* These tests are priced separately and not included in the cost of the AVRT Panel & Physician Consult.

References

  1.  Chao S, Ying J, Liew G, et al. Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case- control study. J Exp Clin Cancer Res. 2013 Jul 23;32:44.Yip KT, Das PK, Suria D, et al.​
  2. Liew CC, Ma J, Tang HC, et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med. 2006 Mar;147(3):126-32.
  3. Marshall KW, Mohr S, Khettabi FE, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 2010 Mar 1;126(5):1177-86.
  4. Seer.cancer.gov Dec 2021 * 5-year Survival Rate
  5. Dempsey A, Chao S, Stamatiou D, et al., Aristotle: A single blood test for pan-cancer screening. Journal of Clinical Oncology. 2020; 38:15_suppl, e15037-e15037
  6. Melander O, Belting M, Manjer J, et al. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer. Cancer Epidemiology and Prevention Biomarkers 23.8 (2014): 1672-1676.
  7. Catalona WJ, Partin AW, Sanda MG, et al. A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. The Journal of Urology. 2011;185(5):1650-1655.
  8. Loeb S, Sanda MG, Broyles DL, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. The Journal of Urology. 2015;193(4):1163-1169
Aristotle, ColonSentry, & BreastSentry tests were developed, and their performance characteristics determined by Stage Zero Life Sciences, Inc.; they have not been cleared or approved by the US Food and Drug Administration. These tests were performed in a CLIA certified laboratory and are intended for clinical purposes. The Aristotle, Prostate Health Index, ColonSentry, & BreastSentry tests must be ordered by and used only in consultation with a healthcare provider.